Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
University of Rochester NCORP Research Base
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03996265
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in cancer survivors.
Intervention
Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Condition
Be Diagnosed With Cancer and Have Completed Systemic Therapy
Investigators
Heather S Jim, William J. Irvin, Bryan A. Faller, Ki Y. Chung, Elie G. Dib, Kathleen J. Yost, Gregory A. Masters, Alison K. Conlin, John A. Ellerton, Jay W. Carlson, Samantha A. Seaward, Alexander Menter, Venkata K. Parsa, Jami A. Fukui, Maria T. Grosse-Perdekamp, Howard M. Gross, Pamala A. Pawloski, Vinay K. Gudena, Bolanle Gbadamosi, Praveen Vashist, Charles H. Shelton, Timothy D. Moore, Namita Sharma, Amarinthia (Amy) Curtis, Thomas J. Summers, Ana M. Ventura, Matthias Weiss, Kamal Kant Singh Abbi, Brian L. Burnette, Chady A. Leon, Site Public Contact,

See list of participating sites